Hiroaki Nakashima
Nagoya University
279 Papers
676 Citations
Hiroaki Nakashima is an academic researcher from Nagoya University. The author has contributed to research in topics: Medicine & Myelopathy. The author has an hindex of 29, co-authored 204 publications. Previous affiliations of Hiroaki Nakashima include University Health Network & Toronto Western Hospital.
Chat about Author
Papers
A Clinical Practice Guideline for the Management of Patients With Degenerative Cervical Myelopathy: Recommendations for Patients With Mild, Moderate, and Severe Disease and Nonmyelopathic Patients With Evidence of Cord Compression
Michael G. Fehlings,Michael G. Fehlings,Lindsay Tetreault,Lindsay Tetreault,K. Daniel Riew,James W. Middleton,Bizhan Aarabi,Paul M. Arnold,Darrel S. Brodke,Anthony S. Burns,Simon Carette,Robert Chen,Kazuhiro Chiba,Joseph R. Dettori,Julio C. Furlan,Julio C. Furlan,James S. Harrop,Langston T. Holly,Sukhvinder Kalsi-Ryan,Mark R. N. Kotter,Brian K. Kwon,Allan R. Martin,James Milligan,James Milligan,Hiroaki Nakashima,Narihito Nagoshi,Narihito Nagoshi,John M. Rhee,Anoushka Singh,Andrea C. Skelly,Sumeet Sodhi,Sumeet Sodhi,Jefferson R. Wilson,Albert Yee,Jeffrey C. Wang +34 more
TL;DR: Recommendations for the management of degenerative cervical myelopathy will promote standardization of care for patients with DCM, decrease the heterogeneity of management strategies and encourage clinicians to make evidence-informed decisions.
A Clinical Practice Guideline for the Management of Patients With Acute Spinal Cord Injury and Central Cord Syndrome: Recommendations on the Timing (≤24 Hours Versus >24 Hours) of Decompressive Surgery
Michael G. Fehlings,Michael G. Fehlings,Lindsay Tetreault,Lindsay Tetreault,Jefferson R. Wilson,Bizhan Aarabi,Paul A. Anderson,Paul M. Arnold,Darrel S. Brodke,Anthony S. Burns,Kazuhiro Chiba,Joseph R. Dettori,Julio C. Furlan,Gregory W.J. Hawryluk,Langston T. Holly,Susan Howley,Tara Jeji,Sukhvinder Kalsi-Ryan,Mark R. N. Kotter,Shekar N. Kurpad,Ralph J. Marino,Allan R. Martin,Eric M. Massicotte,Geno J. Merli,James W. Middleton,Hiroaki Nakashima,Narihito Nagoshi,Narihito Nagoshi,Katherine Palmieri,Anoushka Singh,Andrea C. Skelly,Eve C. Tsai,Alexander R. Vaccaro,Albert Yee,James S. Harrop +34 more
TL;DR: These guidelines should be implemented into clinical practice to improve outcomes in patients with acute SCI and central cord syndrome by promoting standardization of care, decreasing the heterogeneity of management strategies, and encouraging clinicians to make evidence-informed decisions.
A Clinical Practice Guideline for the Management of Patients With Acute Spinal Cord Injury: Recommendations on the Use of Methylprednisolone Sodium Succinate:
Michael G. Fehlings,Michael G. Fehlings,Jefferson R. Wilson,Lindsay Tetreault,Lindsay Tetreault,Bizhan Aarabi,Paul A. Anderson,Paul M. Arnold,Darrel S. Brodke,Anthony S. Burns,Kazuhiro Chiba,Joseph R. Dettori,Julio C. Furlan,Julio C. Furlan,Gregory W.J. Hawryluk,Langston T. Holly,Susan Howley,Tara Jeji,Sukhvinder Kalsi-Ryan,Mark R. N. Kotter,Shekar N. Kurpad,Brian K. Kwon,Ralph J. Marino,Allan R. Martin,Eric M. Massicotte,Geno J. Merli,James W. Middleton,Hiroaki Nakashima,Narihito Nagoshi,Narihito Nagoshi,Katherine Palmieri,Andrea C. Skelly,Anoushka Singh,Eve C. Tsai,Alexander R. Vaccaro,Albert Yee,James S. Harrop +36 more
TL;DR: This guideline is to outline the appropriate use of methylprednisolone sodium succinate (MPSS) in patients with acute spinal cord injury (SCI) and suggest not offering a 48-hour infusion of high-dose MPSS to adult Patients with acute SCI.
Adjacent Segment Disease After Posterior Lumbar Interbody Fusion: Based on Cases With a Minimum of 10 Years of Follow-up
Hiroaki Nakashima,Noriaki Kawakami,Taichi Tsuji,Tetsuya Ohara,Yoshitaka Suzuki,Toshiki Saito,Ayato Nohara,Ryoji Tauchi,Kyotaro Ohta,Nobuyuki Hamajima,Shiro Imagama +10 more
TL;DR: The majority of the reoperations for ASD were performed more than 5 years after the initial lumbar fusion surgery, although the progression of radiographical ASD began in the early postoperative period, and a high degree of pelvic incidence was a risk factor for developing early-onset radiographic ASD.
153
Riluzole as a Neuroprotective Drug for Spinal Cord Injury: From Bench to Bedside
Narihito Nagoshi,Narihito Nagoshi,Hiroaki Nakashima,Hiroaki Nakashima,Michael G. Fehlings,Michael G. Fehlings +5 more
TL;DR: There is convincing evidence that riluzole diminishes neurological tissue destruction and promotes functional recovery in animal SCI models, and existing preclinical evidence, and emerging clinical data in the treatment of SCI.
126